Riverbridge Partners Increased Its Henry Schein (HSIC) Holding; Supernus Pharmaceuticals (SUPN) Sentiment Is 1.1

Henry Schein, Inc. (NASDAQ:HSIC) Logo

Supernus Pharmaceuticals Inc (SUPN) investors sentiment is 1.1 in 2018 Q1. It’s the same as in 2017Q4. The ratio is without change, as only 138 investment managers increased and started new stock positions, while 125 sold and trimmed positions in Supernus Pharmaceuticals Inc. The investment managers in our database now hold: 47.99 million shares, up from 47.19 million shares in 2017Q4. Also, the number of investment managers holding Supernus Pharmaceuticals Inc in top ten stock positions increased from 3 to 4 for an increase of 1. Sold All: 28 Reduced: 97 Increased: 82 New Position: 56.

Riverbridge Partners Llc increased Henry Schein Inc. (HSIC) stake by 11.67% reported in 2018Q1 SEC filing. Riverbridge Partners Llc acquired 45,103 shares as Henry Schein Inc. (HSIC)’s stock rose 4.05%. The Riverbridge Partners Llc holds 431,580 shares with $29.01 million value, up from 386,477 last quarter. Henry Schein Inc. now has $11.19 billion valuation. The stock decreased 1.54% or $1.14 during the last trading session, reaching $72.66. About 1.60 million shares traded or 3.68% up from the average. Henry Schein, Inc. (NASDAQ:HSIC) has declined 23.14% since June 29, 2017 and is downtrending. It has underperformed by 35.71% the S&P500. Some Historical HSIC News: 03/04/2018 – HENRY SCHEIN INC – TRANSACTION EXPECTED TO BE ACCRETIVE AFTER 2018; 23/04/2018 – The deal, which is expected to be announced Monday morning, would combine Henry Schein’s veterinary supplies, software for practices and distribution network with Vets First Choice’s prescription management platform; 10/04/2018 – Alpha Omega-Henry Schein Cares Holocaust Survivors Oral Health Program Receives 2018 William J. Gies Award; 04/04/2018 – HENRY SCHEIN INC HSIC.O : LEERINK RAISES TARGET PRICE TO $80 FROM $75; 23/04/2018 – Henry Schein to Own 63% and Vets First Choice Hldrs to Own 37% of New Co; 03/04/2018 – HENRY SCHEIN INC – FINANCIAL TERMS OF AGREEMENT WERE NOT DISCLOSED; 06/03/2018 – Henry Schein Cares Global Student Outreach Program Supports Student-Led Missions To Underserved Communities Around The World; 04/05/2018 – Henry Schein Introduces Proprietary SLX Clear Aligner System; 16/04/2018 – Henry Schein, Inc. Awards Third Annual Henry Schein Cares Gold Medal To The Night Ministry; 10/04/2018 – Henry Schein at Deutsche Bank Health Care Conference May 9

More notable recent Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) news were published by: Seekingalpha.com which released: “Supernus Pharmaceuticals: Can The Rally Continue?” on June 26, 2018, also Nasdaq.com with their article: “Dr. Carrolee Barlow, MD, Ph.D., Joins Supernus’ Board of Directors” published on June 27, 2018, Seekingalpha.com published: “Supernus Keeps Delivering” on June 05, 2018. More interesting news about Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) were released by: Marketwatch.com and their article: “Dow vies to avoid longest losing streak since 1978, Nasdaq digests break to record territory” published on June 22, 2018 as well as Nasdaq.com‘s news article titled: “Recent Analysis Shows Supernus Pharmaceuticals, R1 RCM, Golar LNG, Chemical Financial, Chipmos Technologies …” with publication date: June 05, 2018.

Ashford Capital Management Inc holds 6.06% of its portfolio in Supernus Pharmaceuticals, Inc. for 880,774 shares. Provident Investment Management Inc. owns 539,536 shares or 3.9% of their US portfolio. Moreover, Falcon Point Capital Llc has 2.47% invested in the company for 269,504 shares. The California-based Neumeier Poma Investment Counsel Llc has invested 2.47% in the stock. Rice Hall James & Associates Llc, a California-based fund reported 1.30 million shares.

Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. The company has market cap of $3.02 billion. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy. It has a 42.5 P/E ratio. The companyÂ’s product candidates comprise SPN-810, a molindone hydrochloride that is in Phase III clinical trial for the treatment of impulsive aggression in patients with attention deficit hyperactivity disorder ; and SPN-812, a viloxazine hydrochloride, which has completed Phase IIb trial that is used for the treatment of ADHD.

The stock increased 0.34% or $0.2 during the last trading session, reaching $58.35. About 652,170 shares traded. Supernus Pharmaceuticals, Inc. (SUPN) has risen 67.64% since June 29, 2017 and is uptrending. It has outperformed by 55.07% the S&P500. Some Historical SUPN News: 13/03/2018 – SUPERNUS PHARMACEUTICALS- TO USE PROCEEDS FROM SALE OF NOTES TO ACQUIRE OR INVEST IN COMPLEMENTARY BUSINESSES, COMPANIES, PRODUCTS AND TECHNOLOGIES; 08/05/2018 – SUPERNUS – FOR 2018, REITERATES ITS PRIOR GUIDANCE FOR NET PRODUCT SALES, RESEARCH AND DEVELOPMENT EXPENSES; 19/04/2018 – DJ Supernus Pharmaceuticals Inc, Inst Holders, 1Q 2018 (SUPN); 13/03/2018 – SUPERNUS PHARMACEUTICALS INC – NOTES WILL MATURE ON APRIL 1, 2023, UNLESS EARLIER REPURCHASED OR CONVERTED; 15/03/2018 – SUPERNUS REPORTS PRICING OF $350M PRIVATE OFFER OF CONV NOTES; 07/03/2018 Norges Bank Buys New 1.1% Position in Supernus; 08/05/2018 – Supernus Pharmaceuticals 1Q Rev $90.4M; 08/05/2018 – SUPERNUS SEES FY NET PRODUCT SALES $375M TO $400M; 08/05/2018 – SUPERNUS 1Q EPS 49C, EST. 33C; 20/03/2018 – Supernus Forms Golden Cross: Technicals

Since January 1, 0001, it had 0 insider purchases, and 13 selling transactions for $19.55 million activity.

Analysts await Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) to report earnings on August, 1. They expect $0.46 earnings per share, up 43.75% or $0.14 from last year’s $0.32 per share. SUPN’s profit will be $23.82M for 31.71 P/E if the $0.46 EPS becomes a reality. After $0.49 actual earnings per share reported by Supernus Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -6.12% negative EPS growth.

Since June 11, 2018, it had 0 insider purchases, and 2 sales for $1.11 million activity. MLOTEK MARK E sold $753,410 worth of Henry Schein, Inc. (NASDAQ:HSIC) on Tuesday, June 12. Another trade for 4,822 shares valued at $351,678 was sold by Brons Paul.

Riverbridge Partners Llc decreased 3M Company (NYSE:MMM) stake by 2,596 shares to 112,015 valued at $24.59M in 2018Q1. It also reduced Fastenal Company (NASDAQ:FAST) stake by 23,700 shares and now owns 1.81M shares. Mobile Mini Inc. (NASDAQ:MINI) was reduced too.

Investors sentiment increased to 0.86 in Q1 2018. Its up 0.03, from 0.83 in 2017Q4. It increased, as 55 investors sold HSIC shares while 169 reduced holdings. 61 funds opened positions while 132 raised stakes. 158.34 million shares or 8.33% more from 146.17 million shares in 2017Q4 were reported. Champlain Invest Prtn Ltd stated it has 0.67% of its portfolio in Henry Schein, Inc. (NASDAQ:HSIC). The Sweden-based Swedbank has invested 0.76% in Henry Schein, Inc. (NASDAQ:HSIC). 145,882 were reported by Pub Employees Retirement Association Of Colorado. Kentucky Retirement Systems accumulated 8,021 shares. Credit Suisse Ag reported 305,903 shares stake. Moreover, Commerce Bancshares has 0.01% invested in Henry Schein, Inc. (NASDAQ:HSIC). 269,529 were accumulated by Jane Street Gp Limited Co. Fifth Third Savings Bank owns 633 shares. Virginia Retirement Et Al accumulated 0.1% or 120,100 shares. Baystate Wealth Mgmt Limited Liability Corporation accumulated 0% or 20 shares. California-based Destination Wealth Mgmt has invested 0% in Henry Schein, Inc. (NASDAQ:HSIC). Eads Heald Inv Counsel invested 0.49% in Henry Schein, Inc. (NASDAQ:HSIC). Moreover, Evergreen Mngmt Limited Liability has 0.29% invested in Henry Schein, Inc. (NASDAQ:HSIC) for 44,223 shares. Assetmark reported 0% stake. Howe And Rusling Incorporated reported 0% in Henry Schein, Inc. (NASDAQ:HSIC).

Among 11 analysts covering Henry Schein (NASDAQ:HSIC), 6 have Buy rating, 0 Sell and 5 Hold. Therefore 55% are positive. Henry Schein has $10200 highest and $71 lowest target. $80.55’s average target is 10.86% above currents $72.66 stock price. Henry Schein had 15 analyst reports since January 5, 2018 according to SRatingsIntel. The firm earned “Hold” rating on Thursday, February 15 by J.P. Morgan. The rating was maintained by Northcoast with “Buy” on Tuesday, April 24. The rating was maintained by Robert W. Baird with “Buy” on Tuesday, April 24. The stock of Henry Schein, Inc. (NASDAQ:HSIC) has “Market Perform” rating given on Wednesday, February 21 by Leerink Swann. The company was maintained on Tuesday, April 24 by Deutsche Bank. Goldman Sachs downgraded it to “Hold” rating and $7200 target in Tuesday, April 24 report. The stock has “Hold” rating by Leerink Swann on Tuesday, February 13. The company was maintained on Friday, March 9 by Robert W. Baird. JP Morgan maintained Henry Schein, Inc. (NASDAQ:HSIC) rating on Thursday, February 15. JP Morgan has “Neutral” rating and $77 target. The firm has “Outperform” rating given on Wednesday, April 4 by Leerink Swann.

Henry Schein, Inc. (NASDAQ:HSIC) Institutional Positions Chart